BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34665475)

  • 1. Toward a postbiotic era of microbiome science: Opportunities to advance immunotherapies for hepatocellular carcinoma.
    Nakatsu G
    J Gastroenterol Hepatol; 2022 Jan; 37(1):34-38. PubMed ID: 34665475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.
    Liu Z; Liu X; Liang J; Liu Y; Hou X; Zhang M; Li Y; Jiang X
    Front Immunol; 2021; 12():765101. PubMed ID: 34675942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can Combined Therapy Benefit Immune Checkpoint Blockade Response in Hepatocellular Carcinoma?
    Zhongqi F; Xiaodong S; Yuguo C; Guoyue L
    Anticancer Agents Med Chem; 2019; 19(2):222-228. PubMed ID: 30426903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microecological regulation in HCC therapy: Gut microbiome enhances ICI treatment.
    Liu X; Li S; Wang L; Ma K
    Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167230. PubMed ID: 38734322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications.
    Hou J; Zhang H; Sun B; Karin M
    J Hepatol; 2020 Jan; 72(1):167-182. PubMed ID: 31449859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome.
    Temraz S; Nassar F; Kreidieh F; Mukherji D; Shamseddine A; Nasr R
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond.
    Lee YH; Tai D; Yip C; Choo SP; Chew V
    Front Immunol; 2020; 11():568759. PubMed ID: 33117354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives.
    Shen KY; Zhu Y; Xie SZ; Qin LX
    J Hematol Oncol; 2024 Apr; 17(1):25. PubMed ID: 38679698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
    Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
    Front Immunol; 2020; 11():1037. PubMed ID: 32547550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions.
    Hato T; Goyal L; Greten TF; Duda DG; Zhu AX
    Hepatology; 2014 Nov; 60(5):1776-82. PubMed ID: 24912948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut microbiome in HCC - Mechanisms, diagnosis and therapy.
    Schwabe RF; Greten TF
    J Hepatol; 2020 Feb; 72(2):230-238. PubMed ID: 31954488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies.
    Giraud J; Chalopin D; Blanc JF; Saleh M
    Front Immunol; 2021; 12():655697. PubMed ID: 33815418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
    Oura K; Morishita A; Tani J; Masaki T
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
    Fu Y; Liu S; Zeng S; Shen H
    J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Zeng P; Shen D; Zeng CH; Chang XF; Teng GJ
    Curr Oncol Rep; 2020 Jun; 22(8):76. PubMed ID: 32596779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical immunometabolism and metabolic reprogramming in liver cancer: Deciphering the role of gut microbiome.
    Golonka RM; Vijay-Kumar M
    Adv Cancer Res; 2021; 149():171-255. PubMed ID: 33579424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological landscape and immunotherapy of hepatocellular carcinoma.
    Prieto J; Melero I; Sangro B
    Nat Rev Gastroenterol Hepatol; 2015 Dec; 12(12):681-700. PubMed ID: 26484443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hepatocellular carcinoma - from immunobiology to immunotherapy].
    Flecken T; Schmidt N; Spangenberg HC; Thimme R
    Z Gastroenterol; 2012 Jan; 50(1):47-56. PubMed ID: 22222798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Bai J; Liang P; Li Q; Feng R; Liu J
    Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.